Item 1.01. Entry into a Material Definitive Agreement.
Amended and Restated Clinical Trial Collaboration and License Agreement
On
The License Agreement, among other things, allocated to GSK additional development rights with respect to the Combination Regimen (as defined below) and provided for funding by GSK of such development activities as well as later stage development and commercial milestone payments to the Company.
Pursuant to the License Agreement, the Company granted GSK a non-exclusive license to patents and know-how controlled by the Company (1) to research and develop belantamab (or any cytotoxic antibody-drug conjugate derived therefrom controlled by GSK, including but not limited to belantamab mafodotin-blmf) (collectively, the “GSK BCMA Products”) and nirogacestat (“Nirogacestat”), either alone together as a combination therapy, or together with additional pharmaceutical agents (the “Combination Regimen”) and (2) to commercialize GSK BCMA Products as part of the applicable Combination Regimen in the Field worldwide. Field in the previous sentence refers to the prevention, treatment and prophylaxis of multiple myeloma and other BCMA-expressing malignancies and diseases. Nothing in the License Agreement requires the Company to convey any rights to intellectual property relevant to the use of Nirogacestat with any compound or substance other than as part of a Combination Regimen.
Pursuant to the License Agreement, GSK will make an equity investment of
The foregoing is only a brief description of certain terms of the License Agreement and the transactions contemplated thereby, does not purport to be a complete description of the rights and obligations of the parties thereunder, and is qualified in its entirety by reference to the License Agreement that will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending
Concurrently with the execution of the License Agreement, on
Pursuant to the Stock Purchase Agreement, subject to certain exceptions, GGL may not sell the Shares without the Company’s approval for a certain period following the closing date of the transactions contemplated therein. In addition, the Stock Purchase Agreement contains a standstill provision and customary representations, warranties, and covenants of each of the Company and GGL.
The foregoing is only a brief description of certain terms of the Stock Purchase Agreement and the transactions contemplated thereby, does not purport to be a complete description of the rights and obligations of the parties thereunder, and is qualified in its entirety by reference to the Stock Purchase Agreement that is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.
Item 3.02. Unregistered Sales of
The information set forth under Item 1.01 relating to the issuance of the Shares is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
*Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the
© Edgar Online, source